Mark Phillips
Compliance Officer at COGNETIVITY NEUROSCIENCES LTD.
Net worth: 10 607 $ as of 29/04/2024
Profile
Mark A.
Phillips is currently the Chairman at Cognetivity Ltd., Director & Chief Compliance Officer at Cognetivity Neurosciences Ltd., Non-Executive Director at Fluorogenics Ltd., and Director at Centillion Technology Ltd.
He previously worked as Senior Vice President-Research & Development at GSK Plc.
Phillips holds a doctorate degree from the University of Cambridge and an undergraduate degree from Loughborough University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 08/11/2022 | 815,934 ( 0.91% ) | 10 607 $ | 29/04/2024 |
Mark Phillips active positions
| Companies | Position | Start |
|---|---|---|
| COGNETIVITY NEUROSCIENCES LTD. | Compliance Officer | 20/12/2017 |
Cognetivity Ltd.
 Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Chairman | 31/12/2013 |
Fluorogenics Ltd.
 Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Director/Board Member | 31/08/2016 |
| Centillion Technology Ltd. | Director/Board Member | 31/12/2020 |
Former positions of Mark Phillips
| Companies | Position | End |
|---|---|---|
| GSK PLC | Chief Tech/Sci/R&D Officer | - |
Training of Mark Phillips
| University of Cambridge | Doctorate Degree |
| Loughborough University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| COGNETIVITY NEUROSCIENCES LTD. | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 3 |
|---|---|
Cognetivity Ltd.
Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Health Technology |
Fluorogenics Ltd.
Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Commercial Services |
| Centillion Technology Ltd. |
- Stock Market
- Insiders
- Mark Phillips
